Keywords: Eli Lilly, Boehringer Ingelheim, Vertex, Jentadueto, Linagliptin, Kalydeco, USA, FDA, Type 2 diabetes, Cystic fibrosis
FDA approves combo diabetes drug Jentadueto and Kalydeco
Article | 01 February 2012
The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
